Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 醫務管理系(所) > 期刊論文 > Item 310902800/34600

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34600

標題:	Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
作者:	Lee, Yu-Ting Tu, Chi-Wen Kam, Kam-Hong Ma, Tsung-Liang Kuo, Chin-Ho Lee, Ming-Yang Hsiao, Chih-Yen Chan, Michael W. Y. Hung, Peir-Haur
貢獻者:	Chia-Yi Christian Hospital National Chung Cheng University National Chung Cheng University National Chung Cheng University Chia-Yi Christian Hospital Chia-Yi Christian Hospital Chia-Yi Christian Hospital Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy & Science Department of Applied Life Science and Health, Chia Nan University of Pharmacy & Science
關鍵字:	renal-disease patients bone-marrow fibrosis anemia hormone therapy
日期:	2022
上傳時間:	2023-12-11 14:00:00 (UTC+8)
出版者:	MDPI
摘要:	Secondary hyperparathyroidism (SHPT) is common in end-stage renal disease (ESRD) patients, and it can suppress erythropoiesis. We aimed to investigate the relationship between the consumption of erythropoiesis-stimulating agents (ESAs) and parathyroidectomy (PTX) in ESRD patients with SHPT and to determine the predictors for anemia improvement. The current standard of chronic kidney disease anemia therapy relies on the prescription of iron supplementation, and ESA. We retrospectively analyzed 81 ESRD patients with PTX at Ditmanson Medical Foundation Chiayi Christian Hospital from July 2004 to Dec 2018. The requirement of ESA therapy markedly declined from a dose of 41.6 (interquartile range [IQR], 0-91.2) to 10.3 (IQR, 0-59.5, p = 0.001) unit/kg/week. In addition, 63.7% of patients required iron replacement therapy preoperatively and the proportion reduced to 52.5% after PTX (p < 0.001). The hemoglobin (Hb) level showed an insignificant change from a median value of 10.7 g/dL (9.5-11.6 g/dL) before PTX to 10.5 g/dL (9.6-11.2 g/dL) at 6 months after PTX. A preoperative Hb level <= 10 mg/dL (odds ratio [OR], 20.1; 95% confidence interval [CI], 4.71-125, p < 0.001) and transferrin saturation (TSAT) < 25% (OR, 12.8; 95% CI, 2.51-129, p < 0.001) were predictors for anemia improvement. Our study demonstrated that PTX markedly decreased the requirement of ESA. Patients with a low preoperative Hb level or low TSAT showed an increase in the Hb level after PTX. PTX may be considered not only for SHPT with refractory anemia but also for high ESA-dependent patients.
關聯:	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.23, n.18, 10391
顯示於類別:	[醫務管理系(所)] 期刊論文 [生活保健科技系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
ijms231810391.pdf		1632Kb	Adobe PDF	36	檢視/開啟
index.html		0Kb	HTML	172	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....